Profile data is unavailable for this security.
About the company
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
- Revenue in USD (TTM)659.00k
- Net income in USD-59.60m
- Incorporated2016
- Employees18.00
- LocationIkena Oncology Inc50 Northern Ave.BOSTON 02210United StatesUSA
- Phone+1 (857) 343-8292
- Fax+1 (302) 655-5049
- Websitehttps://www.ikenaoncology.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc | 0.00 | -6.47m | 91.04m | 10.00 | -- | 12.29 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 93.41m | -- | 5.41 | 0.189 | 48.31 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 93.96m | 45.00 | -- | 1.05 | -- | 27.75 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.33m | 15.00 | 4.68 | 0.5369 | 4.50 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 94.54m | 300.00 | -- | -- | -- | 1.17 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Cidara Therapeutics Inc | 18.86m | -123.53m | 94.78m | 69.00 | -- | 0.8197 | -- | 5.03 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Coherus Biosciences Inc | 304.34m | -450.00k | 94.88m | 235.00 | -- | -- | 19.54 | 0.3118 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Ikena Oncology Inc | 659.00k | -59.60m | 96.14m | 18.00 | -- | 0.6327 | -- | 145.89 | -1.24 | -1.24 | 0.0137 | 2.78 | 0.0036 | -- | -- | 15,325.58 | -32.72 | -29.72 | -35.50 | -34.62 | -- | -- | -9,043.85 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| CervoMed Inc | 9.65m | -5.04m | 97.64m | 8.00 | -- | 1.95 | -- | 10.11 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Hillevax Inc | 0.00 | -150.28m | 98.62m | 90.00 | -- | 0.5315 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 98.88m | 143.00 | -- | 0.4675 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 99.50m | 66.00 | -- | -- | -- | 26.76 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Relmada Therapeutics Inc | 0.00 | -86.49m | 99.57m | 20.00 | -- | 2.09 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 99.61m | 47.00 | -- | 3.12 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 99.77m | 93.00 | 6.91 | 1.05 | 5.53 | 177.21 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Renovaro Inc | 0.00 | -80.65m | 101.87m | 25.00 | -- | 0.7399 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.8513 | 0.00 | -- | -- | 0.00 | -72.84 | -39.86 | -89.56 | -42.11 | -- | -- | -- | -- | -- | -10.76 | 0.0182 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
Data as of Nov 13 2024. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD
21.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 4.77m | 9.88% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.36m | 2.81% |
| Adage Capital Management LPas of 30 Jun 2024 | 987.90k | 2.05% |
| BML Capital Management LLCas of 30 Sep 2024 | 723.29k | 1.50% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 476.40k | 0.99% |
| Acuitas Investments LLCas of 30 Sep 2024 | 449.66k | 0.93% |
| Jacobs Levy Equity Management, Inc.as of 30 Jun 2024 | 424.38k | 0.88% |
| Millennium Management LLCas of 30 Jun 2024 | 354.71k | 0.74% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 349.35k | 0.72% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 325.71k | 0.68% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
